Teofilo Borunda Duque, PharmD, MS

Dr. Teofilo Borunda has been working as a Pharmacist at the Rhodes Group since July 2019.  As a pharmacist, Dr. Borunda designs actionable and real-time targeted interventions for the healthcare system, ultimately aiming to improve the delivery of healthcare. He focuses on using longitudinal clinical laboratory results to design targeted interventions for the optimization of screening, diagnosis, monitoring and treatment of high cost, high risk and high frequency health conditions. His areas of focus are chronic disease management and opioid abuse.

 

​Dr. Borunda earned his Bachelor of Arts in Chemistry from New Mexico State University in 2014. He was awarded a dual PharmD – Master of Science degree from the University of New Mexico College of Pharmacy in 2018. He continued his training and completed a postgraduate fellowship at TriCore Reference Laboratories in 2019.

Specialties

  • Chronic Disease Management

  • Hierarchical Condition Categories (HCC) identification through laboratory data interpretation

  • Clinical Informatics/Analytics

Education

  • Post-Graduate Pharmacy Fellowship, TriCore Reference Laboratories (2019)

  • Doctor of Pharmacy, University of New Mexico College of Pharmacy (2018)

  • Master of Science, University of New Mexico College of Pharmacy (2018)

  • Bachelor of Arts, New Mexico State University (2014)

Certifications/Affiliations

  • New Mexico State Board of Pharmacy: Pharmacist License

  • Pharmacist Preceptor at One Hope Centro de Vida Clinic

  • Clinical Assistant Professor University of New Mexico College of Pharmacy

  • Teaching Certificate

Opportunity for Real-Time, Longitudinal Clinical Laboratory Data to Enhance Diabetes Disease Surveillance: A cross-sectional laboratory database-enabled population study

Journal of Applied Laboratory Medicine, 08.28.2020

With the gradual yearly decrease of reimbursement for laboratory services due to the Protecting Access to Medicare Act (PAMA), it has become imperative for clinical laboratories to diversify and find novel methods that highlight their value. This study supports the value proposition of using laboratory data for diabetes surveillance, as well as a tool for future population health interventions. Using clinical laboratory data is an inexpensive method that can be automated and provide real-time longitudinal insights. Therefore, this method can be a timely way to stratify patients at risk, observe diabetes patterns, and aid public health officials to build more focused targeted interventions.

 

Measuring What Matters: How the Laboratory Contributes Value in the Opioid Crisis

Journal of Applied Laboratory Medicine, 11.01.2020

With over 20 years of the opioid crisis, our collective response has evolved to address the ongoing needs related to the management of opioid use and opioid use disorder. There has been an increasing recognition of the need for standardized metrics to evaluate organizational management and stewardship. The clinical laboratory, with a wealth of objective and quantitative health information, is uniquely poised to support opioid stewardship and drive valuable metrics for opioid prescribing practices and opioid use disorder (OUD) management. To identify laboratory-related insights that support these patient populations, a collection of 5 independent institutions, under the umbrella of the Clinical Laboratory 2.0 movement, developed and prioritized metrics.